Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Geron
(NASDAQ:GERN)
Intraday
$3.6905
-0.0395
[-1.06%]
After-Hours
$3.6905
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$3.6905
-0.0395
[-1.06%]
At close: Apr 19
$3.6905
0
[0.00%]
After Hours: 5:48PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Geron Stock (NASDAQ:GERN)
Geron Stock (NASDAQ: GERN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, April 12, 2024
Argan Reports Upbeat Earnings, Joins Coupang And Other Big Stocks Moving Higher On Friday
Avi Kapoor
-
Apr 12, 2024, 10:19AM
Geron Option Alert: Jun 21 $3 Calls at the Ask: 600 @ $1.15 vs 8051 OI; Earnings 5/9 Before Open [est] Ref=$4.0
Charles Gross
-
Apr 12, 2024, 10:07AM
Thursday, April 11, 2024
Jim Cramer: This Tech Stock Is 'Great,' Archer Aviation Is 'Too Speculative For Me'
Avi Kapoor
-
Apr 11, 2024, 8:37AM
Needham Reiterates Buy on Geron, Maintains $5 Price Target
Benzinga Newsdesk
-
Apr 11, 2024, 6:19AM
Wednesday, April 10, 2024
The Latest Analyst Ratings For Geron
Benzinga Insights
-
Apr 10, 2024, 3:01PM
Wedbush Reiterates Outperform on Geron, Maintains $6 Price Target
Benzinga Newsdesk
-
Apr 10, 2024, 12:53PM
Tuesday, March 19, 2024
Geron Corporation Announces Pricing Of $150M Underwritten Offering Of Common Stock And Pre-Funded Warrants
Benzinga Newsdesk
-
Mar 19, 2024, 9:07AM
Monday, March 18, 2024
STAT News' Adam Feuerstein Publishes "I Was Wrong About Geron's Blood Cancer Drug. Now, Is It A Takeover Target?"; Shares See Volume
Happy Mohamed
-
Mar 18, 2024, 9:08AM
Why Nuvei Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Mar 18, 2024, 8:06AM
Logitech, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Avi Kapoor
-
Mar 18, 2024, 5:57AM
Friday, March 15, 2024
Inflation Squeezes Stocks, Bitcoin Slips To $68,000, While Commodities On Track For Best Week In Months: What's Driving Markets Friday?
Piero Cingari
-
Mar 15, 2024, 2:12PM
Needham Maintains Buy on Geron, Raises Price Target to $5
Benzinga Newsdesk
-
Mar 15, 2024, 1:03PM
What's Going On With Cancer Focused-Geron Stock On Friday?
Vandana Singh
-
Mar 15, 2024, 11:29AM
Goldman Sachs Maintains Buy on Geron, Raises Price Target to $5
Benzinga Newsdesk
-
Mar 15, 2024, 10:44AM
Wedbush Reiterates Outperform on Geron, Maintains $6 Price Target
Benzinga Newsdesk
-
Mar 15, 2024, 9:41AM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
Mar 15, 2024, 9:06AM
Geron shares are trading lower. The company announced that the FDA Oncologic Drugs Advisory Committee voted in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.
Benzinga Newsdesk
-
Mar 15, 2024, 7:54AM
Thursday, March 14, 2024
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
-
Mar 14, 2024, 5:33PM
Geron Stock Is Soaring After Hours: What's Going On?
Adam Eckert
-
Mar 14, 2024, 5:03PM
Geron shares are trading higher after the company announced that the FDA Oncologic Drugs Advisory Committee voted in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.
Benzinga Newsdesk
-
Mar 14, 2024, 4:28PM
Geron Shares Resume Trade
Benzinga Newsdesk
-
Mar 14, 2024, 4:25PM
Trading Halt: Halt status updated at 4:20:00 PM ET: Quotation Resumption: News and Resumption Times
Benzinga Newsdesk
-
Mar 14, 2024, 4:20PM
Geron Announces FDA Oncologic Drugs Advisory Committee Votes In Favor Of The Clinical Benefit/Risk Profile Of Imetelstat For The Treatment Of Transfusion-Dependent Anemia In Patients With Lower-Risk MDS
Benzinga Newsdesk
-
Mar 14, 2024, 3:57PM
FDA Advisers Vote 12-To-2 In Favor Of Benefits Of Geron's Blood Disorder Drug Outweighing Its Risks Based On Late-Stage Trial Data
Benzinga Newsdesk
-
Mar 14, 2024, 3:17PM
Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending
Benzinga Newsdesk
-
Mar 14, 2024, 6:55AM
Wednesday, March 13, 2024
Needham Reiterates Buy on Geron, Maintains $4 Price Target
Benzinga Newsdesk
-
Mar 13, 2024, 6:41AM
Tuesday, March 12, 2024
Why Geron Stock Is Falling Today
Erica Kollmann
-
Mar 12, 2024, 2:43PM
FDA Casts Doubts On Geron's Blood Cancer Drug, But Analyst Sees High Probability For Imetelstat's Potential Approval For MDS Anemia Treatment
Vandana Singh
-
Mar 12, 2024, 2:20PM
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
-
Mar 12, 2024, 2:07PM
Geron shares are trading lower after FDA staff reviewers reportedly said treatment with the company's anemia drug Imetelstat is associated with risks that might be considered substantial.
Benzinga Newsdesk
-
Mar 12, 2024, 12:12PM
FDA Staff Reviewers Say Treatment With Geron's Anemia Drug Imetelstat Is Associated With Risks That Might Be Considered Substantial; It Is Not Clear That Risks Of Treatment With Imetelstat Are Outweighed By The Potential Benefit For The Intended Population; The Patient-Reported Outcomes Are Not Supportive Of Geron's Treatment Effect
Benzinga Newsdesk
-
Mar 12, 2024, 9:38AM
Needham Reiterates Buy on Geron, Maintains $4 Price Target
Benzinga Newsdesk
-
Mar 12, 2024, 5:58AM
Monday, March 04, 2024
Needham Reiterates Buy on Geron, Maintains $4 Price Target
Benzinga Newsdesk
-
Mar 4, 2024, 6:55AM
Wednesday, February 28, 2024
Needham Reiterates Buy on Geron, Maintains $4 Price Target
Benzinga Newsdesk
-
Feb 28, 2024, 11:46AM
Geron Q4 EPS $(0.09) Beats $(0.10) Estimate, Sales $23.00K Miss $70.00K Estimate; $378.1M In Cash, Cash Equivalents, And Marketable Securities Projected To Fund Operating Expenses Into The Third Quarter Of 2025
Benzinga Newsdesk
-
Feb 28, 2024, 7:08AM
Earnings Scheduled For February 28, 2024
Benzinga Insights
-
Feb 28, 2024, 6:24AM
Tuesday, January 30, 2024
Geron Announced FDA Provided Notice That It Scheduled Advisory Committee Meeting Of Oncologic Drugs Advisory Committee As Part Of NDA Review
Benzinga Newsdesk
-
Jan 30, 2024, 8:16AM
Monday, December 11, 2023
Geron Corporation Announced Presentations Of Data From Its IMerge Phase 3 Clinical Trial Evaluating First-In-Class Investigational Telomerase Inhibitor Imetelstat In Patients With MDS, As Well As Population Analysis Of Claims Data In Lower Risk MDS
Benzinga Newsdesk
-
Dec 11, 2023, 4:17PM
Wednesday, December 06, 2023
Geron Announces 50% Enrollment In The Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat In Patients With Relapsed/Refractory Myelofibrosis
Benzinga Newsdesk
-
Dec 6, 2023, 8:14AM
Monday, December 04, 2023
Geron Announced Publication In The Lancet Of Results From IMerge Phase 3 Trial Of Imetelstat Versus Placebo In Patients With Lower-risk Myelodysplastic Syndromes Relapsed/Refractory Or Ineligible For Erythropoiesis-stimulating Agents
Benzinga Newsdesk
-
Dec 4, 2023, 5:02AM
Wednesday, November 29, 2023
Director at Geron Acquires Company Stock Options Worth 200,000 Shares
Benzinga Insights
-
Nov 29, 2023, 10:01AM
Thursday, November 02, 2023
Geron IMerge Phase 3 Presentations At Upcoming ASH Annual Meeting Reinforce Significant Durability And Breadth Of Effect Of Imetelstat In Lower Risk MDS
Benzinga Newsdesk
-
Nov 2, 2023, 9:17AM
Geron's As Of September 30, 2023, Had $381.9M In Cash, Cash Equivalents, And Marketable Securities Expected To Be Sufficient To Fund Its Projected Operating Requirements Through The End Of Q3 2025
Benzinga Newsdesk
-
Nov 2, 2023, 8:03AM
Geron Q3 EPS $(0.08) Beats $(0.10) Estimate, Sales $164.00K Beat $59.00K Estimate
Benzinga Newsdesk
-
Nov 2, 2023, 8:01AM
Earnings Scheduled For November 2, 2023
Benzinga Insights
-
Nov 2, 2023, 4:56AM
Wednesday, November 01, 2023
Geron Earnings Preview
Benzinga Insights
-
Nov 1, 2023, 1:02PM
Wednesday, October 04, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Oct 4, 2023, 12:01PM
Tuesday, October 03, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Oct 3, 2023, 2:37PM
Friday, September 29, 2023
Geron Announced That The European Medicines Agency Has Validated Imetelstat Marketing Authorization Application For Transfusion-dependent Anemia In Patients With Lower-risk Myelodysplastic Syndromes. The Review Is Expected To Be Approximately 14 Months
Benzinga Newsdesk
-
Sep 29, 2023, 8:11AM
Thursday, September 28, 2023
EVP at Geron Acquires Company Stock Options Worth 1,350,000 Shares
Benzinga Insights
-
Sep 28, 2023, 11:00AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch